{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:12:26Z","timestamp":1778803946503,"version":"3.51.4"},"reference-count":62,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,9,29]],"date-time":"2024-09-29T00:00:00Z","timestamp":1727568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Multiple myeloma (MM) is a hematological malignancy and poses significant therapeutic challenges. This review synthesizes evidence from pivotal clinical trials to guide induction treatment for transplant-eligible (TE), newly diagnosed MM (NDMM) patients. Emphasizing the evolution from three-drug to four-drug induction therapies, we highlight the integration of monoclonal antibodies, particularly CD38 recombinant monoclonal antibody agents, into treatment regimens. This analysis includes a comprehensive literature review of research from major databases and conferences conducted between 2010 and 2023, culminating in the detailed evaluation of 47 studies. The findings underscore the superiority of quadruple regimens in TE NDMM, notably those incorporating daratumumab, in achieving superior responses including progression-free survival (PFS), minimal residual disease (MRD) negativity, objective response rate (ORR), and overall survival (OS) when compared to triple-drug regimens. As treatment regimens evolve with additional agents, the improved outcomes with treatment-related adverse events should be carefully balanced. This review advocates for a paradigm shift towards quadruple induction therapies for TE NDMM, offers a detailed insight into the current landscape of MM treatment, and reinforces a new standard of care.<\/jats:p>","DOI":"10.3390\/antib13040080","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T07:19:37Z","timestamp":1727680777000},"page":"80","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Insights from Clinical Trials: Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma"],"prefix":"10.3390","volume":"13","author":[{"given":"Olga","family":"Lytvynova","sequence":"first","affiliation":[{"name":"Cleveland Clinic Akron General, Department of Internal Medicine, Akron, OH 44307, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenna","family":"Jwayyed","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Indiana University, Indianapolis, IN 46202, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Pastel","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Akron General, Department of Internal Medicine, Akron, OH 44307, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4667-1427","authenticated-orcid":false,"given":"Rohan","family":"Prasad","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Akron General, Department of Internal Medicine, Akron, OH 44307, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2473-6528","authenticated-orcid":false,"given":"Jack","family":"Khouri","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louis","family":"Williams","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Mazzoni","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2739-2265","authenticated-orcid":false,"given":"Shahzad","family":"Raza","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6914-7439","authenticated-orcid":false,"given":"Faiz","family":"Anwer","sequence":"additional","affiliation":[{"name":"Cleveland Clinic Foundation, Taussig Cancer Center, Cleveland, OH 44106, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,29]]},"reference":[{"key":"ref_1","unstructured":"American Cancer Society (2024, September 19). Cancer Statistics Center. Published March 31, 2024. Available online: https:\/\/cancerstatisticscenter.cancer.org\/#!\/."},{"key":"ref_2","unstructured":"International Myeloma Working Group (2024, September 19). International Myeloma Working Group (IMWG) Criteria for the Diagnosis of Multiple Myeloma. International Myeloma Foundation. Available online: https:\/\/www.myeloma.org\/international-myeloma-working-group-imwg-criteria-diagnosis-multiple-myeloma."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"(2024, September 19). In Proceedings of the 23rd Congress of the European Hematology Association Stockholm, Sweden, 14\u201317 June 2018; HemaSphere: Stockholm, Sweden, 2018; Volume 2 (Suppl. S1), pp. 1\u20131113, Available online: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6110645\/.","DOI":"10.1097\/HS9.0000000000000060"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"(2024, September 19). In Proceedings of the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians Oral Session (O010-O173); Bone Marrow Transplantation: Baltimore, MD, USA, 2020; Volume 55 (Suppl. S1), pp. 22\u2013174. Available online: https:\/\/www.nature.com\/articles\/s41409-020-01118-4.","DOI":"10.1038\/s41409-020-01119-3"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3406","DOI":"10.1200\/JCO.21.02614","article-title":"Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: A European Myeloma Network (EMN) report within the HARMONY project","volume":"40","author":"Cairns","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_6","unstructured":"National Comprehensive Cancer Network (2024, March 31). NCCN Clinical Practice Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1445."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e418","DOI":"10.1200\/EDBK_159009","article-title":"Updated Diagnostic Criteria and Staging System for Multiple Myeloma","volume":"35","author":"Rajkumar","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and Management of Multiple Myeloma: A Review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Boussi, L.S., Avigan, Z.M., and Rosenblatt, J. (2022). Immunotherapy for the treatment of multiple myeloma. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1027385"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s13045-022-01296-2","article-title":"Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?","volume":"15","author":"Kegyes","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther."},{"key":"ref_14","unstructured":"International Myeloma Foundation (2024, March 27). Multiple Myeloma Drugs. International Myeloma Foundation. Available online: https:\/\/www.myeloma.org\/multiple-myeloma-drugs."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa2312054","article-title":"Daratumumab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"390","author":"Sonneveld","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"LBA-1","DOI":"10.1182\/blood-2023-191911","article-title":"Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial","volume":"142","author":"Sonneveld","year":"2013","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/bjh.18432","article-title":"Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study","volume":"199","author":"Sborov","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_18","first-page":"936","article-title":"Daratumumab, Lenalidomide, Bortezomib, & Dexamethasone for Transplant-eligible Newly Diagnosed Multiple Myeloma: GRIFFIN","volume":"136","author":"Voorhees","year":"2022","journal-title":"Blood J. Am. Soc. Hematol."},{"key":"ref_19","unstructured":"Voorhees, P.M., Kaufman, J.L., Laubach, J., Sborov, D.W., Reeves, B., Rodriguez, C., Chari, A., Silbermann, R., Costa, L.J., and Anderson, L.D. (2022). Depth of Response to Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone Improves over Time in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Griffin Study Update, Springer Nature."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/bloodadvances.2020003642","article-title":"Daratumumab plus VRd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN","volume":"5","author":"Voorhees","year":"2021","journal-title":"Blood Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41408-024-01088-6","article-title":"Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: Final analysis of clinically relevant subgroups in GRIFFIN","volume":"14","author":"Chari","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"8538","DOI":"10.1200\/JCO.2020.38.15_suppl.8538","article-title":"Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA","volume":"38","author":"Touzeau","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"8004","DOI":"10.1200\/JCO.2021.39.15_suppl.8004","article-title":"Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2","volume":"39","author":"Moreau","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.clml.2019.09.004","article-title":"Daratumumab plus bortezomib, thalidomide, and dexamethasone (D-VTD) in transplant-eligible Newly Diagnosed Multiple myeloma (NDMM): Subgroup Analysis of High-risk Patients (PTS) in CASSIOPEIA","volume":"19","author":"Sonneveld","year":"2019","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1200\/JCO.21.01935","article-title":"Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone with Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma","volume":"40","author":"Costa","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_26","first-page":"453","article-title":"Daratumumab plus cyclophosphamide, bortezomib, and dexamethasone induction therapy in multiple myeloma followed by daratumumab maintenance: End-of-study results from lyra","volume":"5","author":"Rifkin","year":"2021","journal-title":"HemaSphere"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.15806","article-title":"Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study","volume":"185","author":"Yimer","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1080\/10428194.2022.2076847","article-title":"Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: Final results of the LYRA study","volume":"63","author":"Yimer","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e810","DOI":"10.1016\/S2352-3026(22)00263-0","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): Part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial","volume":"9","author":"Goldschmidt","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_30","unstructured":"(2024, September 19). Subgroup Analysis of Phase 3 Trial GMMG-HD7 Evaluating Isa-VRd in Patients with High-Risk Cytogenetics. Oncology Practice Management. Available online: https:\/\/oncpracticemanagement.com\/web-exclusive-articles\/2883:subgroup-analysis-of-phase-3-trial-gmmg-hd7-evaluating-isa-VRd-in-patients-with-high-risk-cytogenetics."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood-2021-145097","article-title":"Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplant-eligible multiple myeloma patients: The phase III GMMG-HD7 trial","volume":"138","author":"Goldschmidt","year":"2021","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Mai, E.K., Bertsch, U., Fenk, R., Tichy, D., Besemer, B., D\u00fcrig, J., Schroers, R., von Metzler, I., H\u00e4nel, M., and Mann, C. (2022, January 9\u201317). Isatuximab, lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients with high-risk cytogenetics: A subgroup analysis from the GMMG-HD7 trial. Proceedings of the European Hematology Association Congress, Vienna, Austria.","DOI":"10.1097\/01.HS9.0000846588.94000.04"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Jackson, G.H., Pawlyn, C., Cairns, D.A., de Tute, R.M., Hockaday, A., Collett, C., Jones, J.R., Kishore, B., Garg, M., and Williams, C.D. (2021). Carfilzomib, lenalidomide, dexamethasone, and cyclophosphamide (KRdc) as induction therapy for transplant-eligible, newly diagnosed multiple myeloma patients (Myeloma XI+): Interim analysis of an open-label randomised controlled trial. PLoS Med., 18.","DOI":"10.1371\/journal.pmed.1003454"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1182\/blood.2022018339","article-title":"Optimizing the value of lenalidomide mainten+ance by extended genetic profiling: An analysis of 556 patients in the Myeloma XI trial","volume":"141","author":"Panopoulou","year":"2023","journal-title":"Blood"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(20)30354-9","article-title":"Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial","volume":"8","author":"Usmani","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1182\/blood-2011-11-395749","article-title":"Randomized, multicenter, phase 2 study (EVOLUTION) of combinations of bortezomib, dexamethasone, cyclophosphamide, and lenalidomide in previously untreated multiple myeloma","volume":"119","author":"Kumar","year":"2012","journal-title":"Blood"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/ejh.13349","article-title":"The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma","volume":"104","author":"Okazuka","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.2019000241","article-title":"Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma","volume":"134","author":"Oriol","year":"2019","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","article-title":"Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): A multicentre, open-label, phase 3, randomised, controlled trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_40","first-page":"3192","article-title":"Long-term survival with CYBORD induction therapy in newly diagnosed multiple myeloma","volume":"122","author":"Reeder","year":"2013","journal-title":"Blood"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V114.22.616.616","article-title":"A phase II trial comparison of once versus twice weekly bortezomib in CYBORD chemotherapy for newly diagnosed myeloma: Identical high response rates and less toxicity","volume":"114","author":"Reeder","year":"2009","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1080\/16078454.2022.2032915","article-title":"Bortezomib-cyclophosphamide-dexamethasone induction\/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: Phase 2 multicenter trial","volume":"27","author":"Muranushi","year":"2022","journal-title":"Hematology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/blood.2021010744","article-title":"Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: The IFM KRd final results","volume":"138","author":"Roussel","year":"2021","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","article-title":"Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): A randomized, open-label, phase 2 trial","volume":"22","author":"Gay","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","article-title":"Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: Pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial","volume":"24","author":"Mina","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_46","unstructured":"(2024, July 23). ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/study\/NCT01816971."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"LBA4","DOI":"10.1200\/JCO.2022.40.17_suppl.LBA4","article-title":"Lenalidomide, bortezomib, and dexamethasone (VRd) \u00b1 autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial","volume":"40","author":"Richardson","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1056\/NEJMoa2204925","article-title":"Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma","volume":"387","author":"Richardson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","article-title":"Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma","volume":"376","author":"Attal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e861","DOI":"10.1016\/S2352-3026(20)30323-9","article-title":"Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): Long-term follow-up analysis of a randomised phase 3, open-label study","volume":"7","author":"Tacchetti","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_52","first-page":"S105","article-title":"A triplet bortezomib-and immunomodulator-based therapy before and after double ASCT improves overall survival of newly diagnosed mm patients: Final analysis of phase 3 gimema-MMY-3006 study","volume":"2","author":"Tacchetti","year":"2018","journal-title":"HemaSphere"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.3324\/haematol.2018.205476","article-title":"Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial","volume":"104","author":"Wester","year":"2019","journal-title":"Haematologica"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.2217\/fon-2021-1072","article-title":"Daratumumab utilization and cost analysis among patients with multiple myeloma in a US community oncology setting","volume":"18","author":"Gordan","year":"2022","journal-title":"Future Oncol."},{"key":"ref_55","unstructured":"(2024, September 19). Meeting of the Oncologic Drugs Advisory Committee Meeting Announcement\u201404\/12\/2024. FDA, Available online: https:\/\/www.fda.gov\/advisory-committees\/advisory-committee-calendar\/april-12-2024-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04122024."},{"key":"ref_56","unstructured":"National Cancer Institute (2024, September 19). Clinical Trials Search, Available online: https:\/\/www.cancer.gov\/research\/participate\/clinical-trials-search\/v?loc=0&tid=S1803&rl=2&id=NCI-2018-02465&pn=1&ni=10."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"100929","DOI":"10.1016\/j.blre.2022.100929","article-title":"Current state and next-generation CAR-T cells in multiple myeloma","volume":"54","author":"Manier","year":"2022","journal-title":"Blood Rev."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Kr\u00f6ger, N., Gribben, J., Chabannon, C., Yakoub-Agha, I., and Einsele, H. (2022). Multiple myeloma. The EBMT\/EHA CAR-T Cell Handbook, Springer. Chapter 16.","DOI":"10.1007\/978-3-030-94353-0"},{"key":"ref_59","unstructured":"EUCTR GR (2024, September 19). A Multicenter, Open-Label, Randomized Phase II Study Comparing Daratumumab Combined with Bortezomib-Cyclophosphamide-Dexamethasone (DARA-VCD) versus the Association of Bortezomib-Thalidomide-Dexamethasone (VTD) as Pre-Transplant Induction and Post-Transplant Consolidation, both followed by a Maintenance Phase with Ixazomib Alone or in Combination with Daratumumab, in Newly Diagnosed Multiple Myeloma (MM) Young Patients Eligible for Autologous Stem Cell Transplantation. Available online: https:\/\/trialsearch.who.int\/trial2.aspx?trialid=EUCTR2018-002089-37-GR."},{"key":"ref_60","unstructured":"EUCTR GR (2024, September 19). A Study of Combination of Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) Compared to VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants with Previously Untreated Multiple Myeloma, Available online: https:\/\/www.clinicaltrials.gov\/study\/NCT03652064."},{"key":"ref_61","unstructured":"(2024, September 19). Daratumumab-Bortezomib-Dexamethasone (Dara-VCD) vs. Bortezomib-Thalidomide-Dexamethasone (VTd) then Maintenance with Ixazomib (IXA) or IXA-Dara\u2014Full Text View, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03896737."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6590","DOI":"10.1182\/blood-2023-190335","article-title":"Evidence-Based Recommendations for Induction Treatment of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients; A Scoping Review","volume":"142","author":"Lytvynova","year":"2023","journal-title":"Blood"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/4\/80\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:06:40Z","timestamp":1760112400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/13\/4\/80"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,29]]},"references-count":62,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["antib13040080"],"URL":"https:\/\/doi.org\/10.3390\/antib13040080","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,29]]}}}